
Cahit Birdir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7296477/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A review of image processing methods for fetal head and brain analysis in ultrasound images. Computer Methods and Programs in Biomedicine, 2022, 215, 106629.	4.7	25
2	Placenta accreta spectrum disorders—experience of management in a German tertiary perinatal centre. Archives of Gynecology and Obstetrics, 2021, 303, 1451-1460.	1.7	11
3	Evaluation of carcinoembryonic antigenâ€related cell adhesion molecule 1 blood serum levels in women at high risk for preeclampsia. American Journal of Reproductive Immunology, 2021, 85, e13375.	1.2	1
4	Are two children at once better than one? Risk analysis of twin pregnancies and births after assisted reproduction. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 264, 76-82.	1.1	3
5	MR-proANP, a cardiovascular biomarker to predict late-onset preeclampsia and intrauterine growth restricted fetuses. Pregnancy Hypertension, 2020, 22, 54-58.	1.4	0
6	Prenatal Prediction of Outcome by Fetal Gastroschisis in a Tertiary Referral Center. Diagnostics, 2020, 10, 540.	2.6	8
7	Predictive value of sFlt-1, PIGF, sFlt-1/PIGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37â€ ⁻ weeks of pregnancy. Pregnancy Hypertension, 2018, 12, 124-128.	1.4	54
8	Afamin: an early predictor of preeclampsia. Archives of Gynecology and Obstetrics, 2018, 298, 1009-1016.	1.7	18
9	Soluble B7â€H4 blood serum levels are elevated in women at high risk for preeclampsia in the first trimester, as well as in patients with confirmed preeclampsia. American Journal of Reproductive Immunology, 2018, 80, e12988.	1.2	11
10	Impact of maternal serum levels of Visfatin, AFP, PAPP-A, sFlt-1 and PIGF at 11–13 weeks gestation on small for gestational age births. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 629-634.	1.5	12
11	Follistatin during pregnancy and its potential role as an ovarian suppressing agent. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 212, 150-154.	1.1	8
12	Preeclampsia in Fetal Medicine. Ultraschall in Der Medizin, 2017, 38, 589-590.	1.5	0
13	Serum concentrations of soluble B7â€H4 in early pregnancy are elevated in women with preterm premature rupture of fetal membranes. American Journal of Reproductive Immunology, 2016, 76, 149-154.	1.2	11
14	Detection of circulating trophoblast particles in maternal blood using density gradient centrifugation in preeclampsia and in normotensive pregnancies. Hypertension in Pregnancy, 2016, 35, 323-329.	1.1	6
15	Maternal serum copeptin, MR-proANP and procalcitonin levels at 11–13Âweeks gestation in the prediction of preeclampsia. Archives of Gynecology and Obstetrics, 2015, 292, 1033-1042.	1.7	21
16	Change of anti-Mullerian-hormone levels during follicular phase in PCOS patients. Gynecological Endocrinology, 2015, 31, 26-30.	1.7	6
17	Maternal serum anti-Müllerian hormone at 11–13 weeks' gestation in the prediction of preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2015, 28, 865-868.	1.5	15
18	Idiopathic polyhydramnios and fetal gender. Archives of Gynecology and Obstetrics, 2015, 291, 987-991.	1.7	9

CAHIT BIRDIR

#	Article	IF	CITATIONS
19	Reply to "Questions about and speculations on the incidence of idiopathic polyhydramnios by fetal gender― Archives of Gynecology and Obstetrics, 2015, 291, 1197-1197.	1.7	0
20	Embryo Reduction in Dichorionic Triplets to Dichorionic Twins by Intrafetal Laser. Fetal Diagnosis and Therapy, 2014, 35, 83-86.	1.4	17
21	Anti-Mullerian-hormone levels during pregnancy and postpartum. Reproductive Biology and Endocrinology, 2013, 11, 60.	3.3	67
22	Maternal serum tumour necrosis factor receptor 1 (TNF-R1) at 30–33 weeks in the prediction of preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 763-767.	1.5	3
23	Noninvasive Prenatal Testing for Fetal Trisomies in a Routinely Screened First-Trimester Population. Obstetrical and Gynecological Survey, 2013, 68, 173-175.	0.4	13
24	First-Trimester Screening for Neural Tube Defects Using Alpha-Fetoprotein. Fetal Diagnosis and Therapy, 2012, 31, 109-114.	1.4	38
25	Early Detection of Maternal Risk for Preeclampsia. ISRN Obstetrics & Gynecology, 2012, 2012, 1-7.	1.2	20
26	Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. American Journal of Obstetrics and Gynecology, 2012, 207, 374.e1-374.e6.	1.3	323
27	Chromosome-selective sequencing of maternal plasma cell–free DNA for first-trimester detection of trisomy 21 and trisomy 18. American Journal of Obstetrics and Gynecology, 2012, 206, 322.e1-322.e5.	1.3	245
28	First-Trimester Screening for Trisomy 21 with Adjustment for Biochemical Results of Previous Pregnancies. Fetal Diagnosis and Therapy, 2011, 30, 194-202.	1.4	8
29	Placental Growth Factor: A Predictive Marker for Preeclampsia?. Gynakologisch-geburtshilfliche Rundschau, 2009, 49, 94-99.	0.9	19
30	Altered angiogenesis in preeclampsia: evaluation of a new test system for measuring placental growth factor. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1504-10.	2.3	9